drugset
Drugs / apricitabine
last change May 2012 re-read 2 minutes ago

apricitabine

also known as Apricitabina · AVX754 · BCH-10618 · BCH-10652, (-)- · SPD -754

Small molecule

Developed for
HIV infectious disease
Investigated by
Avexa

Trials 6 · a red edge is where a trial was stopped

today NCT00686270 · Ph 3 NCT00612898 · Ph 2/3 NCT00367952 · Ph 2 NCT00352066 · Ph 1 NCT00334659 · Ph 1 NCT00126880 · Ph 2
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT00352066 Jul → Aug 2006 HIV infectious disease Avexa Completed No outcome recorded
Phase 1 NCT00334659 Jun → Aug 2006 HIV infectious disease Avexa Completed No outcome recorded
Phase 22 trials
Phase 2 NCT00367952 Aug 2006 → Jan 2010 HIV infectious disease Avexa Completed No outcome recorded
Phase 2 NCT00126880 Jul 2005 → Jan 2008 HIV infectious disease Avexa Completed No outcome recorded
Phase 2/31 trial
Phase 2/3 NCT00612898 Feb 2008 → Jan 2010 HIV infectious disease Avexa Terminated No outcome recorded
Phase 31 trial
Phase 3 NCT00686270 May 2008 → May 2012 HIV infectious disease Avexa Withdrawn No outcome recorded

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as apricitabine ClinicalTrials.gov intervention name — accepted as the source's own label NCT00686270 ↗
4

NCT00367952 ↗

NCT00352066 ↗

NCT00612898 ↗

NCT00334659 ↗
Known as Apricitabina ChEMBL registry synonym — accepted as the source's own label CHEMBL210651 ↗
Known as AVX754 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00126880 ↗
Known as BCH-10618 ChEMBL registry synonym — accepted as the source's own label CHEMBL210651 ↗
Known as BCH-10652, (-)- ChEMBL registry synonym — accepted as the source's own label CHEMBL210651 ↗
Known as SPD -754 ChEMBL registry synonym — accepted as the source's own label CHEMBL210651 ↗
Action Inhibit “Nucleoside Reverse Transcriptase Inhibitor [NRTI]” NCT00126880 ↗
Modality Small molecule “Nucleoside Reverse Transcriptase Inhibitor [NRTI]” NCT00126880 ↗
1

CHEMBL210651 ↗
Route Oral “800mg apricitabine twice daily orally for 96 weeks” NCT00367952 ↗